新闻
- 说明
The issue of replacing imported goods with their domestic counterparts is particularly acute for Russia today: the large-scale sanctions imposed against the Russian Federation recently have gone “live”. At the same time, there are enterprises in the Urals that have been working for a long time under the import substitution program and, perhaps, have prepared better than others for the events that have come: about one of these productions — in the “Federalpress” material.
- 说明
The ban on the import of medicines and raw materials for their production into Russia by foreign companies is becoming an incentive for the rapid development of domestic pharmaceuticals. The pharmaceutical company Medsintez is a leading plant in the Urals for the production of medicines. Its representatives declare: “It is a high-tech production which is able to provide the Russian market with almost any import-substituting drugs, which is facilitated by a strong scientifi c base of the enterprise and its powerful equipment.” Indeed, the quality of the company’s products has been marked with the highest awards, and the production itself is a guarantor of drug safety in Russia. We learned about the history of the Medsintez innovative plant, its capabilities, its own development of raw materials, expansion of the product line, international cooperation, as well as the development and import substitution in the field of pharmaceuticals at the enterprise.
- 说明
- 说明
2020年9月18日，在俄罗斯塔斯社（叶卡捷琳堡）举行了一次新闻发布会，专门介绍了在俄罗斯和中国对抗新冠状病毒感染中使用药物“三氮唑核苷（Triazavirin）”的国际经验。
- 说明
俄罗斯的医疗合成制品工厂(Medsintez) 是产生重要和必要的药品创新的制药公司。如今，该工正在俄罗斯医疗保健需求最旺盛的地区之一开发，并开发出用于治疗糖尿病的药物。我们介绍企业在现代生物技术产品市场中的工作。